• 1
    Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93:34153.
  • 2
    Lapeyssonnie L. Cerebrospinal meningitis in Africa. Bull World Health Organ 1963;28 (Suppl 1):114.
  • 3
    Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196210.
  • 4
    World Health Organization. Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec 2000;75:3069.
  • 5
    Reingold AL, Broome CV, Hightower AW et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:1148.
  • 6
    LaForce FM, Konde K, Viviani S, Préziosi MP. The meningitis vaccine project. Vaccine 2007;25 (Suppl 1):A97100.
  • 7
    World Health Organization. Risk of epidemic meningitis in Africa: a cause for concern. Wkly Epidemiol Rec 2007;82:7987.
  • 8
    LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27 (Suppl 2):B139.
  • 9
    Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa – has anything changed? Trop Med Int Health 2006;11:77380.
  • 10
    Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:153647.
  • 11
    Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 1982;37:2058.
  • 12
    Guerin PJ, Naess LM, Fogg C et al. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl Trop Dis 2008;2:e342.
  • 13
    Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27 (Suppl 2):1126.
  • 14
    Peltola H, Mäkelä H, Käyhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297:68691.
  • 15
    Campagne G, Garba A, Fabre P et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000;19:14450.
  • 16
    Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:2004.
  • 17
    Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 1996;275:1499503.
  • 18
    Maslanka SE, Gheesling LL, LiButti DE et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997;4:15667.
  • 19
    Amir J, Liang X, Granoff DM. Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b. Pediatr Res 1990;27:35864.
  • 20
    Gorringe AR, van Alphen L. 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines. Hum Vaccin 2009;5:536.
  • 21
    Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 1995;154:4195202.
  • 22
    Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992;267:148994.
  • 23
    Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:236670.
  • 24
    Granoff DM, Maslanka SE, Carlone GM et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:47985.
  • 25
    Joseph H, Ryall R, Bybel M et al. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J Infect Dis 2003;187:11426.
  • 26
    Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R. Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J Infect Dis 2001;184:6612.
  • 27
    Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:837.
  • 28
    Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999;118:4027.
  • 29
    Romero-Steiner S, Holder PF, Gomez de Leon P, Spear W, Hennessy TW, Carlone GM. Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies. Clin Diagn Lab Immunol 2005;12:102935.
  • 30
    Holder PK, Maslanka SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995;2:1327.
  • 31
    Carlone GM, Frasch CE, Siber GR et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol 1992;30:1549.
  • 32
    Plikaytis BD, Holder PF, Pais LB, Maslanka SE, Gheesling LL, Carlone GM. Determination of parallelism and nonparallelism in bioassay dilution curves. J Clin Microbiol 1994;32:24417.
  • 33
    Mäkelä PH, Käyhty H, Weckström P, Sivonen A, Renkonen OV. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975;2:8836.
  • 34
    Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:11125.
  • 35
    Harris SL, Tsao H, Ashton L, Goldblatt D, Fernsten P. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol 2007;14:397403.
  • 36
    Goldblatt D. Simple solid phase assays of avidity. In: JohnstoneAP, TurnerMW, eds. Immunochemistry 2: A Practical Approach. Oxford: Oxford University Press, 1997:3151. ISBN: 0199636095.
  • 37
    Lucas AH, Granoff DM. Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr Infect Dis J 2001;20:2359.
  • 38
    Lucas AH, Reason DC. Polysaccharide vaccines as probes of antibody repertoires in man. Immunol Rev 1999;171:89104.
  • 39
    Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:1603.
  • 40
    Weinand RG, Conrad M. Maturation of the immune response: a computational model. J Theor Biol 1988;133:40928.
  • 41
    Romero-Steiner S, Fernandez J, Biltoft C et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 2001;8:11159.
  • 42
    Al Mazrou Y, Khalil M, Borrow R et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun 2005;73:29329.
  • 43
    Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine 2005;23:97783.
  • 44
    Jokhdar H, Borrow R, Sultan A et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004;11:838.
  • 45
    Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:7614.
  • 46
    Southern J, Deane S, Ashton L et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004;11:11004.
  • 47
    Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000;28:1937.
  • 48
    Anttila M, Eskola J, Ahman H, Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998;177:161421.
  • 49
    McCloskey N, Turner MW, Goldblatt TD. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 1997;205:6772.
  • 50
    Wuorimaa T, Dagan R, Väkeväinen M et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001;184:12115.
  • 51
    WHO Strategic Advisory Group of Experts. Use of fractional doses of meningococcal polysaccharide vaccines for the control of epidemic meningococcal disease in Africa in a context of vaccine shortage. 2007.